SINGH BROTHERS FINED RS 2,600 CR FOR HIDING FACTS FROM DAIICHI

New Delhi, Medicare News, May 15, 2016

Billionaire businessman Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been fined nearly Rs 2,600 crore, media reports say.
The erstwhile promoters of drug maker Ranbaxy were penalised for concealing and misrepresenting facts from Japanese pharmaceutical company, Daiichi Sankyo about its 2008 deal involving the sale of controlling stake in Ranbaxy.

The fine was decided by Singapore International Arbitration Centre (SIAC), which heard an arbitration case filed by Daiichi Sankyo in 2013. The Singh brothers, former Ranbaxy owners, had sold their stake to Daiichi Sankyo for $2.4 billion in 2008.

Japanese drugmaker Daiichi Sankyo later sold Ranbaxy to Mumbai-based Sun Pharma. The Singh brothers now run hospitals under the Fortis brand. They also own financial services firm Religare Enterprises.

Related Posts

  • News
  • May 27, 2025
  • 216 views
Ramping Up Community for JeevanRaksha during Disasters

CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

  • News
  • February 1, 2025
  • 325 views
Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

New Delhi: Healthcare leaders expressed overall satisfaction over Union Budget 2025 except for a letdown or two. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), though appreciated…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

ED raids three pharma units in Baddi, Nalagarh

ED raids three pharma units in Baddi, Nalagarh

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations